

Your genomic test result can help you choose the right treatment

Why Did My Doctor Order This Test?


When it comes to treatment decisions for patients diagnosed with early-stage, localized prostate cancer, one size does not fit all. The Oncotype DX Genomic Prostate Score® (GPS™) test can help your doctor determine if active surveillance is right for you or if your treatment may need to be more aggressive, such as surgery or radiation. The results provide important information including your risk of prostate cancer death and the chances of the cancer spreading in the next 10 years. With so many things to consider, side effects, quality of life, and more, this test can help you find the treatment plan that fits your life.



Lloyd W.
Oncotype DX®
GPS™ patient.
Navigating prostate
cancer since 2012.

Genomic Testing – The Key to Knowing Your Cancer

Unlike a genetic test which assesses your hereditary risk for cancer, a genomic test analyzes cancer tissue to provide information on how a tumor might behave. It identifies changes in DNA that may be driving the growth of your tumor. By providing vital information such as how likely your cancer is to spread, genomic testing can help you and your doctor select an appropriate treatment course.†



How Does it Work?


	<p>1. The tissue from your cancer that has already been biopsied or removed is sent to our lab for a analysis. No additional procedures are required.</p>
	<p>2. Test results are sent to your doctor.</p>
	<p>3. You and your doctor review the results together.</p>

Your Oncotype DX® GPS™ test result can help you and your doctor determine what type of treatment is right for you based on your tumor's characteristics.

† - Loeb, Ross. *Curr Opin Urol*. 2017.

What Can I Expect from My Test Results?

Your results are reported as a Genomic Prostate Score® (GPS™) result on a scale of 0-100. A high GPS result indicates that more aggressive treatment may be appropriate.



How aggressive is my cancer?

Your GPS result can help you understand whether your cancer is likely to recur, spread from the original location to other organs or lymph nodes (metastasis), or result in prostate cancer-specific death within 10 years.

Am I a candidate for active surveillance?

There are many different treatment options for prostate cancer - each with its own set of risks and side effects. Your GPS™ result can help you and your doctor determine an appropriate course of treatment for you.

Over 1.5 million prostate, colon, and breast cancer patients have used an Oncotype DX® test to help guide their treatment decisions.*


The GPS™ test provides a personalized assessment of your cancer, helping you and your doctor discuss next steps with confidence.** Talk to your doctor today about how the Oncotype DX® GPS™ test can be used to help inform your treatment decisions.

* - Data on file

** - Badani et al. Urol Pract 2015

Be Involved with Your Test Results

Schedule your follow-up appointment to discuss your GPS™ test result so you and your doctor can discuss your treatment options. Most clinically low-risk prostate cancers can be safely managed by active surveillance. Through regularly scheduled checkups and testing, you and your provider can monitor your cancer, delaying or avoiding treatments like surgery or radiation altogether.



“My Oncotype DX Genomic Prostate Score® result helped determine that my early-stage cancer was not aggressive, meaning that I could choose active surveillance instead of invasive treatment.”

*Lloyd W.,
Prostate Cancer Patient*

If you would like to share your story with other patients about your experience with the Oncotype DX Genomic Prostate Score test, please contact us at:
patientstories@exactsciences.com.

Learn More About Your Insurance Options

89% of Oncotype DX® GPS™ assay patients have \$0 financial responsibility.***

To learn about Medicare coverage, private insurance coverage and financial assistance, contact our Customer Service group by phone at:

888-ONCOTYPE (888-662-6897)
– select option 2

or by email at:

oncotype@exactsciences.com.

Exact Sciences offers financial assistance for eligible patients. If eligible, both insured and uninsured patients will have no out-of-pocket costs.



Scan here to see if you're eligible for testing at no cost, or visit:
ExactSciencesPO.com/assistance for more information.

EXACT SCIENCES

*** This calculation includes patients with Medicare, Medicare Advantage, Medicaid, Managed Medicaid and commercial insurance. Patient cost-sharing amounts, including deductibles and copays, will vary by plan and coverage type. Only your insurance provider can confirm if and how the Oncotype DX GPS assay will be covered. The number cited is based on historical patient billing data from 1/02/2021 to 12/31/2021. Rates of coverage vary by state and region. Exceptions for coverage may apply. Exact Sciences strongly encourages patients to contact their insurer with questions about Oncotype DX Genomic Prostate Score assay coverage.

Oncotype DX, Oncotype DX Genomic Prostate Score, and Genomic Prostate Score are registered trademarks, and GPS is a trademark of Genomic Health, Inc., a wholly owned subsidiary of Exact Sciences Corporation. © 2022 Genomic Health, Inc. All rights reserved. M-US-GPS-00370.

This educational piece is not designed to provide individual advice in connection with your diagnosis or treatment plan. Talk to your health care provider about such matters and whether the Oncotype DX Genomic Prostate Score® (GPS™) test may be right for you. The actual patients shown here used the Oncotype DX Genomic Prostate Score® (GPS™) test in making their treatment decisions with their physicians. Individual results may vary.